130916-41-5Relevant academic research and scientific papers
TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS
-
Page/Page column 102, (2019/07/19)
The present invention relates to 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepine derivatives of general formula (I) and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof which are centrally and/or peripherally acting V1a receptor modulators, particularly V1a receptor antagonists. Additional subject of the present invention is the process for the preparation of the compounds and the intermediates of the preparation process as well. The invention also relates to the pharmaceutical compositions containing the compounds or together with one or more other active substances, as well as to the use in the treatment and/or prophylaxis of a disease or condition associated with V1a receptor function.
Synthesis of 6h-pyrido[4,3-b]carbazoles
Modi, Sandeep P.,McComb, Todd,Zayed, Abdel-Hadi,Oglesby, R. Christopher,Archer, Sydney
, p. 5555 - 5562 (2007/10/02)
A few 6H-pyrido[4,3-b]carbazoles were prepared for cytotoxicity testing in cultures of human lung cancer cells. Methyl 6-methoxyindoleacetate 13, prepared by reduction of methyl 4-(2-nitro-5-methoxyphenyl)-3-oxobutyrate 11, was condensed with 3-acetylpyri
